MedWatch

2curex raises ambitions for launch: "There is a trend in the market that is working to our advantage"

The launch of 2curex's first product later this year will be bigger and more ambitious than previously expected.

CEO Ole Thastrup (left) with medical director Henrik Harling and head of business development Maarten van der Linden. | Foto: 2curex / PR

2020 may be a transformative year for Danish company 2curex.

Almost 14 years after it was founded, the company plans to bring its product Inditreat to the market, where it will help cancer doctors choose medical treatments, first for bowel cancer, and later, for other types of cancer.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Sanofi dropper udvikling af mRNA-vaccine mod covid-19

Moderna samt Pfizer og Biontech har sat sig så effektivt på markedet for mRNA-vacciner mod covid-19, at Sanofi nu dropper selskabets kandidat inden for samme teknologi - satser i stedet på mere traditionel vaccine-teknologi.

Relaterede

Trial banner

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier